EdiGene to Present Exciting Preclinical Data for Leaper 2.0 In Vivo RNA Editing Therapies at ASGCT Annual Meeting
Transformative Gene-Editing Therapies: A Game-Changer in Medical Innovation Introduction EdiGene, Inc., a clinical-stage biotechnology company based in Beijing, recently made a groundbreaking announcement at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT). They presented preclinical proof-of-concept (POC) data in non-human primate (NHP) models for LEAPERTM 2.0-based in vivo RNA…